Author: admin

  • ‘Humanity is facing a reckoning’: Venice film festival shrugs off the glamour to take aim at politics | Venice film festival

    ‘Humanity is facing a reckoning’: Venice film festival shrugs off the glamour to take aim at politics | Venice film festival

    For most of its 82 years, Venice has been perceived as the world’s most glamorous film festival. This year was no exception: stars including Julia Roberts, Cate Blanchett, Jude Law and George Clooney dutifully waved from canals and trooped down red carpets (although Law tripped while on a water taxi and Clooney got ill).

    But the films themselves struck a different note. Jury president Alexander Payne may have rebutted questions about current affairs during his opening press conference, declaring himself concerned only with discussing cinema, but cinema at Venice this year was concerned largely, it turned out, with discussing current events.

    The big hits of the festival were both nailbiting ticking-clock stories – directed by women – that tackled real-world situations of such tragedy and magnitude that many people shy from discussing them, let alone make a movie about them.

    Towards the end of the festival, The Voice of Hind Rajab, Kaouther Ben Hania’s dramatisation of the killing by the Israel Defense Forces of a five-year-old girl in Gaza, earned a 23-minute standing ovation, as well as chants around the auditorium of “Free Palestine”.

    The film uses the real audio of Rajab’s phone call with emergency call handlers, where she pleads to be rescued from the car in which she was trapped after Israeli tank fire killed the family members around her. During the January 2024 incident, the ambulance sent to reach Rajab also came under attack and the two paramedics on board were killed. Rajab’s body, as well as those of her relatives and the paramedics were found 12 days later.

    Speaking in Venice, Ben Hania said: “I just felt I had to do something, so I wasn’t complicit. I have no political power. I’m not an activist. All I have is this one tool that I have mastered a little bit – cinema. At least, with this film, I wasn’t silenced.”

    ‘The film is an invitation to decide what to do about all these weapons’ … from left: Idris Elba, Kathryn Bigelow and Rebecca Ferguson at a photocall for A House of Dynamite. Photograph: Riccardo Antimiani/EPA

    Meanwhile, Kathryn Bigelow’s first film in eight years, A House of Dynamite, put audiences repeatedly through the 18 minute period from the launch of a nuclear strike on the US until its landing, from the point of view of, variously, a soldier, military leader and the president (played by Idris Elba). Bigelow said she had made the film in an desperate attempt to kickstart conversations about a nuclear treaty.

    “The film is an invitation to decide what to do about all these weapons,” she said. “How is annihilating the world a good defensive measure?”

    Elsewhere, the evidence mounted that cinema is increasingly acting as a quasi-urgent response unit to help audiences interpret a chaotic world. Yorgos Lanthimos’s latest, Bugonia, stars Emma Stone as a high-powered executive kidnapped by conspiracy theorists convinced she is an alien intent on destroying Earth. Confirming the film as an allegory for inertia over tackling a climate catastrophe, its director said: “Humanity is facing a reckoning very soon. People need to choose the right path, otherwise, I don’t know how much time [we have] left.”

    Meanwhile, No Other Choice, the latest from Oldboy’s Park Chan-wook, was a satire about a long-serving employee fired from his role in a manufacturing plant who feels forced to eliminate all competitors for a future post. “We all harbour that deep fear of employment insecurity,” said Park. “Anyone who’s out there trying to make a living in the current modern capitalist society.”

    Playing Vladimir Putin … Jude Law and Paul Dano in The Wizard of the Kremlin. Photograph: Carole Bethuel

    Guillermo del Toro’s Frankenstein engaged with the ethics of AI, though he claimed otherwise, and Law was in town playing Vladimir Putin in Olivier Assayas’s The Wizard of the Kremlin. While Law sought to downplay the film’s contemporary relevance, his director was less abashed, declaring: “The film is very much about how modern politics, 21st-century politics, was invented, and part of that evil raised from the rise to power of Vladimir Putin in Russia.”

    Such eagerness by film-makers for direct political engagement appears unlikely to wane. Announcing their lineup on Friday, the San Sebastián film festival director also issued a long statement calling for end to the “genocide … the unimaginable massacres to which the government of Benjamin Netanyahu is subjecting the Palestinian people.”

    Meanwhile in London on Wednesday evening, Hugh Bonneville took an ITV reporter by surprise when he began his comments on the red carpet by saying: “What’s about to happen in Gaza City is indefensible. The international community must do more to bring it to an end.” He then continued: “Downton Abbey’s a lovely film.”

    Continue Reading

  • Kennedy Center ticket sales take a nosedive after Trump takeover | Trump administration

    Kennedy Center ticket sales take a nosedive after Trump takeover | Trump administration

    Ticket sales at the Kennedy Center have continued to plummet following Donald Trump’s takeover of Washington DC’s premier performing arts venue, with the prestigious Stuttgart Ballet expected to dance next month to houses less than 20% full.

    Audiences are “voting with their feet to skip out” on shows that would once have been packed, in protest at the US president inserting himself into the center’s management and operations as its new chairman, amid discussions around the notion of renaming it after Trump, according to an analysis by the Washingtonian magazine.

    The outlet said the Stuttgart Ballet’s series at the Kennedy complex’s Opera House in October is only “between 4 and 19%” full based on reservations so far, and BodyTraffic, a Los Angeles troupe booked for two performances in the smaller Eisenhower Theatre at the end of the month, is only booked so far at 12% capacity.

    “Big yikes,” one current Kennedy Center staffer told the outlet, having been granted anonymity to speak for fear of retaliation by its new leadership team of Trump-installed loyalists and acolytes.

    Richard Grenell, Trump’s longtime foreign policy adviser who was appointed to lead the Kennedy Center in February after a clear-out of trustees, last week fired its dance programming team and hired in its place a former company member of the Washington Ballet who calls himself a “Maga former dancer”, referring to the Republican leadership slogan “Make America Great Again”.

    Stephen Nakagawa, the Daily Beast reported, is a critic of what he calls “radical leftist ideologies” in ballet, and is a good fit for Trump’s efforts “to reshape the center into a ‘non-woke’ entertainment destination”.

    The Washingtonian report paints a damning portrait of the health of the John F Kennedy Center for the Performing Arts in the months since its takeover by Trump, who last month announced he had decided “reluctantly” to personally host its annual arts awards signature show in December.

    Subscription revenue is down by about 50%, the magazine’s report said, and it quoted a spokesperson for the German embassy who said they did not know if the Stuttgart Ballet would still perform there given the poor ticket sales.

    The reported slump extends an already worrying slide in patronage. By June, the Kennedy Center had seen subscription sales fall by about $1.6m, or roughly 36%, compared with 2024.

    skip past newsletter promotion

    At least 10 cast members from the North American touring production of Les Misérables chose to boycott an 11 June performance there in protest at Trump being in the audience.

    The Kennedy Center did not immediately return a request for comment on Friday.

    Continue Reading

  • MD Anderson Research Highlights for September 5, 2025

    MD Anderson Research Highlights for September 5, 2025

    HOUSTON, SEPTEMBER 5, 2025 ― The University of Texas MD Anderson Cancer Center’s Research Highlights showcases the latest breakthroughs in cancer care, research and prevention. These advances are made possible through seamless collaboration between MD Anderson’s world-leading clinicians and scientists, bringing discoveries from the lab to the clinic and back. 

    Targeted radiation helps patients with kidney cancer delay systemic therapy 
    Read summary | Read in Lancet Oncology

    Some patients with clear cell renal cell carcinoma (ccRCC) – the most common type of kidney cancer in adults – experience oligometastatic disease, where the cancer has spread to only a few sites. Patients with oligometastatic ccRCC often are treated with whole-body systemic treatments like immunotherapy and targeted therapy, which are effective but can come with unwanted side effects. A Phase II clinical trial led by Chad Tang, M.D., and Pavlos Msaouel, M.D., Ph.D., explored the use of metastasis-directed targeted radiation therapy to avoid or delay systemic treatments. In a cohort of 121 patients, survival remained high, with 94% of patients alive at two years and 87% at three years. Overall, patients went a median of 34 months without needing systemic treatment. Researchers also used a novel circulating tumor DNA (ctDNA) test to look for traces of cancer. Patients with no detectable disease stayed off systemic treatments twice as long as those with detectable traces, which suggests that this marker may help select patients for this treatment strategy in the future. These data originally were presented at the American Association for Cancer Research (AACR) Annual Meeting 2025 in April.

    Final trial data from ELI-002 cancer immunotherapy vaccine reinforce promising results
    Read summary | Read in Nature Medicine 

    In initial results from the AMPLIFY-201 trial, co-led by Shubham Pant, M.D., an immunotherapy vaccine targeting the lymph nodes showed potential in delaying relapse of KRAS-mutated pancreatic and colorectal cancers for patients who had previously undergone surgery. Long-term final follow-up data of this vaccine, ELI-002 2P, now shows that 17 of 25 patients (68%) had robust T cell responses, which were associated with increased survival. At 24 months, the median recurrence-free survival had not yet been reached for the higher response group – including all of the patients at the highest two dose levels – with 75% of them still relapse-free, compared to three months for patients who were not high responders. These data prompted the initiation of a Phase II trial that is currently ongoing and includes a new formulation of the vaccine (ELI-002 7P) targeting additional KRAS mutations. 

    Triple combination therapy shows promise for treatment-resistant microsatellite stable BRAF V600E-mutant metastatic colorectal cancer
    Read summary | Read in Cancer Cell

    The BRAF V600E gene mutation makes colorectal cancers (CRCs) more aggressive, leading to poorer survival rates. While some CRCs with high microsatellite instability respond well to immunotherapy, most BRAF V600E-mutant metastatic CRCs are microsatellite stable (MSS) and do not benefit from these treatments. The combination of encorafenib and cetuximab is Food and Drug Administration (FDA)-approved but has limited duration of response in these patients, which led Van Morris, M.D., and colleagues at MD Anderson to examine the safety and efficacy of adding the anti-PD-1 antibody nivolumab to this combination in patients with MSS BRAF V600E-mutant metastatic CRC. This Phase I/II trial enrolled 26 patients and showed an overall response rate of 50%, with a median progression-free survival of over seven months. RNA analysis from liquid biopsies identified distinct patterns of response among patients who did or did not benefit from the triple combination. The positive outcomes of this study led to the launch of SWOG S2107, a nationwide Phase II trial in the same patient population, also led by Morris. 

    Novel sequencing technology links DNA and RNA to provide molecular insights into breast cancer progression
    Read summary | Read in Cell

    Breast cancer often starts in the epithelial cells lining the milk ducts and lobules, but there are many subtypes that make it challenging to identify the cancer’s starting point within normal tissue. Researchers led by Nicholas Navin, Ph.D., developed a new single-cell DNA and RNA sequencing technology – called wellDR-seq – to identify ancestral breast cancer cells. By studying the impact of chromosome gains or losses on gene expression, the researchers were able to uncover the molecular aspects of why some breast cancers are more aggressive or invasive.  The researchers profiled 33,646 single cells from 12 estrogen-receptor (ER)-positive breast cancers, quantifying the amount of certain genes that are actively expressed in tumor cells, as well as the number of copies of specific genes or chromosome segments and their genetic changes over time. These results provide insights into cancer initiation and invasion. While this technique was applied to cancer research, it can also be used to understand the molecular biology of other diseases.

    Large-scale CRISPR screening in stomach organoids reveals gene-drug interactions
    Read summary | Read in Nature Communications 

    Scientists often use organoids – laboratory-grown human cell culture systems that closely mimic body organs – to gain deeper insights into cancer biology and understand how tumors respond to drugs. Researchers led by Yuan-Hung Lo, Ph.D., used organoids along with several CRISPR  gene editing tools to study how cisplatin chemotherapy interacts with different genes in the human stomach. The screens revealed an unexpected link between cisplatin sensitivity and fucosylation, a process that adds sugar molecules to cells. The researchers identified the TAF6L gene as a key regulator of cell recovery from cisplatin-induced cytotoxicity. These results show that CRISPR genetic screens in organoids are a powerful way to identify drug-gene interactions that might explain why some people respond better to certain treatments. 

    First-in-class pan-KRAS inhibitor shows strong antitumor activity in preclinical models
    Read summary | Read in Science Translational Medicine

    KRAS is the most commonly mutated gene in cancer, but targeting the mutant protein is notoriously difficult because current therapies work only for certain KRAS mutations. This led researchers Kathleen McAndrews, Ph.D., Anirban Maitra, M.B.B.S., Raghu Kalluri, M.D., Ph.D., and Timothy Heffernan, Ph.D., to examine the efficacy of a first-in-class inhibitor called BI-2493. This pan-KRAS inhibitor can target the mutant protein in multiple cancer types, regardless of the specific mutation present. BI-2493 was developed as part of the strategic collaboration between Boehringer Ingelheim and MD Anderson. In several models of pancreatic cancer, BI-2493 effectively suppressed tumor growth in vitro and prolonged survival in vivo, with further analysis showing confirmed RAS pathway inhibition. BI-2493 also remodeled the tumor microenvironment of immune-compromised models, increasing intratumoral immune cells and decreasing myeloid cells, allowing for better immunotherapy response. These findings highlight the therapeutic potential of combining BI-2493 with other treatments to inhibit a variety of KRAS mutations and improve patient outcomes. 

    High-dose chemotherapy improves outcomes for multiply relapsed and refractory germ-cell tumors
    Read summary | Read in Clinical Cancer Research

    Testicular cancer is the most common malignancy in young men ages 15 to 35. Most patients respond well to cisplatin-based chemotherapy, with cure rates for metastatic disease as high as 70-80%, but some patients have tumors that relapse. High-dose chemotherapy (HDC) can be effective for some patients after an initial relapse, but outcomes are poor for those with multiple relapses or refractory tumors. In a Phase II trial, researchers led by Yago Nieto, M.D., Ph.D., examined the safety and efficacy of a new HDC specifically targeting DNA damage repair in combination with the targeted therapy bevacizumab. The trial enrolled 65 patients with multiply relapsed and heavily pretreated testicular and other germ-cell tumors. The five-year relapse-free and overall survival rates were 54% and 55.5%, respectively, exceeding expectations. However, the addition of bevacizumab did not improve outcomes. These results were subsequently validated in a prospective cohort of 100 patients with similar poor prognosis, highlighting the promising impact of targeting DNA damage repair pathways to improve outcomes for these patients. 

    Fluorescent tracer helps identify precancerous lesions in pancreatic cancer models
    Read summary | Read in Clinical Cancer Research

    During surgical treatment for pancreatic cancer, pre-malignant pancreatic lesions – which can develop into pancreatic cancer – often go unnoticed and can later cause recurrence. Researchers led by Charles Manning, Ph.D., investigated whether a new fluorescent imaging agent, V-1520, could better identify these areas for removal. V-1520 works by locating and binding to a specific protein biomarker that is overexpressed in high-risk tumor-associated macrophages within the pancreatic tumor microenvironment. Once bound, it emits near-infrared light that can be detected by imaging equipment, allowing surgeons to visualize high-risk areas during surgery. Notably, preclinical models showed a strong uptake of V-1520 in cancer-associated inflammation, but not in pancreatitis – a common but benign condition. Since V-1520 does not target tumors directly and instead binds to overexpressed proteins in the tumor microenvironment, this early detection strategy could also be effective in other cancer types. 

    Researchers identify predictive biomarkers for oral cancer metastasis
    Read summary | Read in PLOS Genetics

    Most oral cancers start in squamous cells lining the mouth and tongue, and frequently metastasize to the lymph nodes. To identify potential biomarkers that predict this metastasis, researchers led by Koichi Takahashi, M.D., Ph.D., and Ken Furudate, D.M.D., Ph.D., performed a comprehensive spatial analysis of the tumor microenvironment surrounding oral cancer cells that metastasized to the lymph nodes. They found increased levels of a specific type of activated supportive cell, called myofibroblastic cancer-associated fibroblasts (myCAFs), located within the invasive tumor front. The researchers showed that cancer cells don’t act alone, and are, instead, aided by these myCAF “accomplices.” The researchers also characterized several key players in the metastasis pathway, extracting a spatial molecular fingerprint to create a 23-gene signature that can predict lymph node metastasis and poor prognosis in patients with oral cancer.

    Honors and Awards

    – 30 –


    Continue Reading

  • Violins & golf swings: Explaining Djokovic & Alcaraz's US Open celebrations – ATP Tour

    1. Violins & golf swings: Explaining Djokovic & Alcaraz’s US Open celebrations  ATP Tour
    2. US Open 2025: Novak Djokovic does ‘Soda Pop Dance’ from K-pop Demon Hunters on court, celebrates daughter’s birthday  Mint
    3. ‘KPop Demo Hunters At Flushing Meadows’: Novak Djokovic’s Shout-Out To Daughter At US Open| Watch  News18
    4. Watch: Novak Djokovic dancing to K-Pop song Soda Pop to celebrate daughter’s birthday at US Open  Gulf News
    5. US Open 2025 – Daddy Novak Djokovic Gives Surprise Birthday Gift to Daughter Tara Djokovic After Quarter-final Win Over Taylor Fritz  The Playoffs

    Continue Reading

  • F1 – Norris quickest in FP2 at Monza ahead of Leclerc and Sainz 

    F1 – Norris quickest in FP2 at Monza ahead of Leclerc and Sainz 

    McLaren’s Lando Norris went quickest in the second practice session for the 2025 FIA Formula 1 Italian Grand Prix with Ferrari’s Charles Leclerc just eight tenths of a second off the Briton as Williams’ Carlos Sainz took P3 ahead of championship leader Oscar Piastri. 

    After handing his car over to McLaren test driver Alex Dunne in FP1, Oscar Piastri was one of the first on track at the start of the session and the Australian was quickly into the groove, despite reporting that one of his mirrors was cracked. 

    The championship leader posted a time of 1:21.212. Team-mate and title rival Lando Norris went quicker, however, and he took top spot with a time of 1:21.012. Aston Martin’s Fernando Alonso slotted into third place ahead of Mercedes’ George Russell with Max Verstappen in P5. 

    However, with nine minutes gone the red flags came out when Kimi Antonelli lost control of the other Mercedes in the second Lesmo and the local hero ended up beached in the gravel. 

    The session resumed after just six minutes and Ferrari’s Charles Leclerc, on Hard tyres, quickly jumped up to P1 with a time of 1:20.957. Verstappen set a session-best second sector time, however, and he moved ahead of Leclerc with a lap of 1:20.710, 0.247s clear of the Ferrari. 

    Carlos Sainz, on Medium tyres, then posted the fastest first sector to steal P1 from the Dutchman by a little over a tenth of a second. The Spaniard’s team-mate Alex Albon also rose up the timesheet, slotting into P3, three tenths off the pace despite a lurid moment in the second Lesmo that he did well to control. 

    Norris and Sainz then bolted on Soft tyres and the McLaren driver went top on 1:19.878, almost four tenths ahead the Williams man. Sauber’s Nico Hülkenberg, also on Soft tyres, briefly took P2 before Albon delivered a clean lap to take second place, 0.301s off Norris. 

    Sainz then returned to P2 ahead of Hamilton, Albon and Hulkenberg as Red Bull’s Yuki Tsunoda popped up to sixth place on his Soft tyre run. 

    Verstappen, however, bailed on his first Soft tyre run, complaining that his RB21 was “very jumpy”. He went for a second flyer and moved up to fourth place, two tenths of Norris. Piastri was next across the line but the Australian was only able to take his McLaren up to third, 0.181s behind team-mate Norris. That soon became fourth as Leclerc climbed to P2 just 0.083s off top spot. 

    With the qualifying sims complete the field moved to harder compounds and longer runs. There was a nervous moment for Leclerc in the final ten minutes when he had a lock up into the Ascari chicane and bounced through the gravel.

    Norris, then, held on to top spot ahead of Leclerc, Sainz and Piastri, with Hamilton in fifth ahead of Verstappen. Albon finished in seventh place ahead of Hülkenberg and Tsunoda finished the session in ninth place, just ahead of Russell. 

    2025 FIA Formula 1 Italian Grand Prix – Free Practice 2
    1 Lando Norris McLaren/Mercedes 1:19.878 28 261.083
    2 Charles Leclerc Ferrari 1:19.961 0.083 29 260.812
    3 Carlos Sainz Williams/Mercedes 1:19.974 0.096 30 260.769
    4 Oscar Piastri McLaren/Mercedes 1:20.059 0.181 29 260.492
    5 Lewis Hamilton Ferrari 1:20.070 0.192 26 260.457
    6 Max Verstappen Red Bull/Honda RBPT 1:20.077 0.199 27 260.434
    7 Alexander Albon Williams/Mercedes 1:20.179 0.301 28 260.103
    8 Nico Hülkenberg Sauber/Ferrari 1:20.241 0.363 27 259.902
    9 Yuki Tsunoda Red Bull/Honda RBPT 1:20.269 0.391 28 259.811
    10 George Russell Mercedes 1:20.276 0.398 29 259.788
    11 Isack Hadjar Racing Bulls/Honda RBPT 1:20.383 0.505 24 259.442
    12 Gabriel Bortoleto Sauber/Ferrari 1:20.475 0.597 25 259.146
    13 Lance Stroll Aston Martin/Mercedes 1:20.528 0.650 28 258.975
    14 Oliver Bearman Haas/Ferrari 1:20.607 0.729 29 258.721
    15 Fernando Alonso Aston Martin/Mercedes 1:20.645 0.767 26 258.600
    16 Esteban Ocon Haas/Ferrari 1:20.654 0.776 29 258.571
    17 Liam Lawson Racing Bulls/Honda RBPT 1:20.811 0.933 25 258.068
    18 Pierre Gasly Alpine/Renault 1:21.102 1.224 30 257.142
    19 Kimi Antonelli Mercedes 1:21.367 1.489 4 256.305
    20 Franco Colapinto Alpine/Renault 1:21.564 1.686 30 255.686

    Continue Reading

  • The World Is On the Verge of Wiping Out Polio — So Why Did Germany Cut Funding Now?

    The World Is On the Verge of Wiping Out Polio — So Why Did Germany Cut Funding Now?

    The world is close to wiping out polio, and that in itself is close to miraculous. Of the thousands of diseases that afflict humans, only one, smallpox, has ever been eradicated before.

    But despite tremendous progress, polio isn’t going down without a fight. Budget cuts, vaccination gaps, and difficulties reaching hard-to-access communities keep pushing the finish line further back. As cases creep upward, virus strains have re-emerged in countries that were long ago declared polio free — including Germany.

    What makes that even more worrying? Germany is one of the latest countries to cut down its international aid budget, planning to trim €17 million from polio vaccination efforts alone in 2025 and 2026. These financial shortfalls could end up accelerating polio’s spread, ushering in a future where resurgences become the norm.

    We spoke with the World Health Organization (WHO) to find out exactly how Germany’s budget cuts could spell future trouble for all of global health.

    But First — What Exactly Is Polio? 

    Poliomyelitis, or polio, is a highly infectious virus that spreads mainly through contaminated water and food, mostly striking children under five. It usually settles in the gut but can eventually attack the central nervous system. Its symptoms are brutal, ranging from fever, headaches, and vomiting, to irreversible paralysis in about 1 of every 200 infections. In the worst cases it can even paralyze breathing muscles, causing suffocation. In fact, a horrific outbreak of polio in Copenhagen in 1952 prompted doctors to create the first ‘iron lung’ — a precursor to today’s hospital intensive care units (ICUs). 

    Before vaccines entered the picture in the 1960s, there were more than 600,000 cases recorded worldwide each year. There’s still no cure — but it can be prevented, which is partially why global health advocates set their sights on the goal of eradicating it entirely.

    As Dr. Shahin Huseynov, Regional Advisor at the WHO Regional Office for Europe, explained, “The chance of success in eradicating polio is unique.” While the virus is incredibly contagious, unlike coronaviruses or monkeypox, it can’t infect animals — eliminating a loop of cross-contamination and putting victory within reach.

    How the World United to Fight Back

    In 1988, the Global Polio Eradication Initiative (GPEI) launched as a partnership between major global health heavy-hitters like WHO, UNICEF, the US Center for Disease Control, the Gates Foundation, Rotary International, Gavi, and others. With two powerful vaccines introduced — the cheap, accessible oral polio vaccine (OPV) delivered by drops, and the highly effective injectable inactivated polio vaccine (IPV) — global immunization campaigns began, driving infections down by 99%.

    In the 1980s, wild poliovirus paralyzed about 1,000 children daily. But by 2021, cases had dwindled to single digits. “To date, 20 million cases of paralysis have been prevented — one of humanity’s greatest achievements in global health. The eradication of the second disease in history after smallpox seems within reach,” said Dr. Huseynov.

    In wealthy nations with strong healthcare systems and widespread vaccination resources, fears of polio have largely become a relic of history. Germany, for instance, saw its last case of wild polio decades ago in 1990.

    So How Has Polio Stuck Around? 

    Total eradication requires closing every elusive immunization gap worldwide at once — a daunting task. At-risk communities face a litany of obstacles including faltering funding, conflict, weak infrastructure, misinformation, and slipping vaccination rates, leaving openings for the virus to proliferate.

    Still, GPEI has scored some major triumphs. India was declared polio-free in 2014, as well as the entire African continent in 2020. And as Dr. Huseynov emphasized: “The polio program is more than just a vaccination program. It strengthens local health systems and achieves success even in crisis areas.”

    “GPEI health workers have provided the infrastructure for COVID-19 vaccination campaigns, fought Ebola outbreaks, taken malaria prevention measures, and continuously improved disease surveillance. Even in the recent conflict in the Gaza Strip, a humanitarian pause allowed children to be vaccinated — a measure that was only possible thanks to the existing infrastructure of the polio program.”

    Yet challenges remain. Wild polio is still endemic in Afghanistan and Pakistan, where political instability, misinformation, and rural inaccessibility fuel setbacks. COVID-19 also paid polio a huge favor by disrupting global childhood immunization campaigns. “If the international community fails now, the virus will return. Models predict 200,000 children will be paralyzed each year if this happens, including in Europe,” added Dr. Huseynov.

    If that happens, decades of effort and billions of dollars will have been effectively wasted. 

    How Polio Bounces Back 

    Another chilling complication? Variant, or vaccine-derived poliovirus (VDPV). Though rare, this emerges when weakened strains from the OPV are able to spread and end up mutating and strengthening, threatening unvaccinated communities and immunocompromised individuals. In 2024, variants of poliovirus were found in 38 countries worldwide, including Palestine and Yemen. Since 2022, VDPV has been found everywhere from Jerusalem, London, Finland, Spain, Poland, and New York City — where an unvaccinated young man subsequently developed polio, leaving him paralyzed.

    And as Dr. Huseynov warned, Germany has also found VDPV in wastewater across major cities since late 2024, including Munich, Berlin, Bonn, Cologne, Hamburg, Dresden, Düsseldorf, Stuttgart, and Mainz. “This is an alarming signal. It highlights the fact that even in Germany and other high-income countries of Europe, there is a risk of infection for people who are not adequately protected against the virus. Combating the disease at its source is therefore crucial also for the protection of public health in Germany.”

    The Cost of Cutting Budgets

    Currently, polio eradication campaigns are like a game of whack-a-mole — but to finish the job, every outbreak everywhere must be stopped, all at once. That requires steady international coordination, along with harmonious synchronization of vaccine supply, access, political will, public demand, and crucially, funding to back it all up.

    GPEI relies primarily on governments and NGOs for its financial support. Dr. Huseynov explained, “Significant reductions to the GPEI’s budget mean certain activities, like disease surveillance and critical immunity building, may not be able to continue everywhere… Not least, the withdrawal of the US from key areas of global health financing once again highlights that multilateral solutions are more important than ever.”

    Germany is GPEI’s historic third-largest donor. Since its founding, it has donated €854 million — proportionally, this means Germany has helped GPEI immunize 123 million children and avert 824,000 cases of paralysis since 1988. At the 2022 World Health Summit in Berlin, it pledged €72 million over 2022–2026. But now it’s looking to cut €17 million over the next two years — nearly half its commitment for that time frame. “These cuts not only send the wrong signal to other countries, but also jeopardize the successes achieved by GPEI.” Based on previous calculations, this cut could result in 2.6 million fewer vaccinated children around 17,700 children at risk of lifelong paralysis. 

    Dr. Huseynov also explained that Germany’s funding isn’t earmarked for any specific region or program, making its contribution extra impactful as it gives GPEI flexibility to direct resources where they’re needed most. With less to work with, campaigns could face delays and difficult trade-offs. And left unchecked, viruses will inevitably spill across borders, creating the perfect conditions for a global health crisis to spiral. 

    New Donors on the Horizon?

    GPEI’s endgame strategy requires $6.9 billion through 2029. While some wealthy nations are stepping back, others are stepping up: Pakistan is funding more of its own efforts through subsidized loans, Saudi Arabia pledged $500 million earlier this year, and the UAE funded a large-scale campaign after last year’s outbreak in Gaza.

    But fragile states facing outbreaks today like Afghanistan, Somalia, and Yemen still lack the resources to do the same. Without sustained commitments from long-standing donors like Germany, eradication will keep slipping out of reach — giving the virus time to evolve and spread as the world stumbles at the finish line.

    Near-Victory Isn’t Enough

    Eradicating polio for all is still possible — but viruses thrive amid negligence. Global health depends not just on scientific breakthroughs, but also simple human choices. Whether world leaders use the tools we have at hand, or fail to, determines health outcomes for all.

    Many in Germany and across the Global North have never experienced polio, making it easy to dismiss its gravity. But the stakes are generational. As Dr. Huseynov emphasized, “With prioritization of health security, Germany has a unique chance to regain a leadership role in the fight against polio and in safeguarding the health of Europe.”

    The finish line is in sight. Now is the time to double down, not pull back. Memories may be short — but the consequences of failing to act could last lifetimes.


    Continue Reading

  • Dr. Pechuho inaugurates national cervical cancer vaccination campaign

    Dr. Pechuho inaugurates national cervical cancer vaccination campaign

    – Advertisement –

    NAWABSHAH, Sep 05 (APP):Provincial Minister for Health and Population Welfare, Dr. Azra Fazal Pechuho, inaugurated the national cervical cancer vaccination campaign here on Friday.

    Deputy Commissioner Shaheed Benazirabad, Abdul Samad Nizamani was also present on the occasion.

    Speaking at the ceremony, Dr. Pechuho said that the Health Department is taking all possible steps to provide quality medical facilities to the public. She added that the cervical cancer prevention campaign will begin on September 15 across Shaheed Benazirabad district. Minister urged parents to fully cooperate with the health department and ensure their daughters receive the vaccine during this national drive.

    District Health Officer Dr. Asadullah Dahri informed that the national cervical cancer vaccination campaign will run from September 15 to 29.

    DHO said that during this period, around 166,000 girls aged 9 to 14 years will be vaccinated. He said that for the campaign, 126 vaccination teams and 86 supervisors have been deployed.

    He further noted that the provision of motorcycles and the mobile vaccination van by the provincial minister would greatly assist vaccinators in achieving the set target.

    On the occasion, Minister Pechuho distributed 50 motorcycles among district vaccinators and handed over a mobile vaccination van to the District Health Officer (DHO) for field vaccination.

    The event was also attended by Chairman District Council Ali Akbar Jamali, Dr. Allah Bux Rajpar, Dr. Riaz Shah, Dr. Amina Brohi, Dr. Aslam Pervez Dahri, District Education Officer Muhammad Saleem Bhatti, Sohrab Mari, and other officials of the Health Department.

    Continue Reading

  • Luke Browning on pole in Monza after late red flag

    Luke Browning on pole in Monza after late red flag

    Hitech TGR driver Luke Browning earned his first Pole Position in FIA Formula 2, setting a 1m 32.390s for the top spot in Monza.

    The Briton set his best effort in the closing stages, but there had been time for one more attempt until a crash for title contender Richard Verschoor brought out the fed flags.

    It was the third and final stoppage of a truncated session, and Qualifying did not resume due to how little time remained following the MP Motorsport driver’s spin into the barriers at Turn 6.

    Verschoor had wound up second at the chequered flag, however in line with the Sporting Regulations in Formula 2, he was deemed the sole cause of the red flag and, as a result, had his fastest time of the session deleted.

    It dropped him from P2 in the results down to P14 where he is now set to start both the Sprint and Feature Races from.

    The Dutchman’s demotion left Kush Maini to benefit and move up to P2 for DAMS Lucas Oil, with Roman Stanek of Invicta Racing promoted to third.

    Goethe moved up to fourth and was followed by Alexander Dunne in fifth after the Irishman’s FP1 outing with McLaren earlier in the day.

    Arvid Lindblad was P6 ahead of Joshua Duerksen, Championship leader Leonardo Fornaroli in eighth, Sami Meguetounif and Dino Beganovic. The Swede is now set to start Saturday’s Sprint Race from reverse grid pole having been promoted up one position from P11.

    For an in-depth report of the F2 Qualifying session, head to the official website.

    Continue Reading

  • An animal sedative keeps turning up in opioid deaths – what you need to know about medetomidine

    An animal sedative keeps turning up in opioid deaths – what you need to know about medetomidine

    A dangerous new drug adulterant is spreading through America’s illicit opioid supply, and it’s making overdoses significantly harder to reverse. Medetomidine, a veterinary sedative normally used to sedate pets, is increasingly being mixed with heroin and fentanyl, creating a cocktail that experts warn could be far deadlier than previous street drug combinations.

    Known as “flysky” on the streets, this animal tranquilliser has already been linked to at least two overdose deaths in Pennsylvania and represents a troubling evolution in the continuing opioid crisis. Unlike traditional opioid overdoses, those involving medetomidine can’t be effectively treated with naloxone, the medication paramedics use to reverse overdoses.

    The emergence of medetomidine mirrors the earlier spread of xylazine, another veterinary sedative that earned the nickname “zombie drug” for its ability to cause severe, treatment-resistant skin wounds. The earliest confirmed detection of medetomidine as a street drug adulterant occurred in Maryland, where it was found in a synthetic opioid mixture probably containing fentanyl.

    From there, the drug spread rapidly. Traces appeared across multiple US states and into Canada, and by early 2024, medetomidine was linked to overdose clusters in Philadelphia and other locations, following the same geographical pattern that xylazine had taken years earlier.

    Unfortunately, opioid-overdose reversal drugs don’t work against veterinary tranquillisers.
    rblfmr/Shutterstock.com

    What makes medetomidine particularly concerning is its extraordinary potency. Medetomidine is an alpha-2 adrenergic receptor agonist – a type of drug that affects the nervous system. While approved only for veterinary use in the UK to sedate animals and provide pain relief for pets, experts estimate it may be 200 to 300 times more potent than xylazine when used as a drug adulterant.

    This extreme potency means that even tiny amounts can have devastating effects. Users experiencing medetomidine-laced drug overdoses typically display extreme drowsiness, muscle twitching, dangerously low heart rate and blood pressure, and laboured breathing.

    Chicago cases from 2024 revealed additional concerning symptoms: extremely high blood pressure, severe confusion and critically low blood oxygen levels – often dropping below 90%, a threshold that can cause organ damage.

    Perhaps most alarming is medetomidine’s resistance to naloxone, the opioid overdose-reversal drug that has saved countless lives. While naloxone can counteract heroin and fentanyl by blocking opioid receptors in the brain, medetomidine affects the body through entirely different pathways. This means there is no approved antidote for medetomidine poisoning, leaving healthcare professionals with limited options when treating overdoses involving this adulterant.

    The withdrawal process is equally tricky. Philadelphia health officials report that people withdrawing from medetomidine-laced drugs experience dangerous spikes in blood pressure and heart rate – symptoms severe enough to trigger a heart attack in some cases. Users also endure uncontrollable nausea and vomiting, intense anxiety, restlessness and violent shaking.

    Understanding why dealers add these veterinary drugs to street opioids requires examining the economics of the illicit drug trade. According to a 2022 DEA report, a kilogram of xylazine powder can be bought from Chinese suppliers for as little as U$6.00 (£4.44). This rock-bottom pricing allows drug traffickers to increase their profit margins significantly while making weak or diluted opioid batches feel more potent to users.

    These sedatives also serve as effective cutting agents (substances used to add bulk and weight to drugs without requiring expensive active ingredients). For dealers, it’s a win-win. They can stretch their supply while creating a product that feels stronger and lasts longer than pure opioids alone.

    Managing new drug adulterants like medetomidine presents unique difficulties for both medical professionals and law enforcement. The drugs make intoxication and withdrawal symptoms more severe and complicated, while also making it harder to identify which specific substance is causing particular symptoms in a patient.

    Medetomidine compounds these problems because it’s rapidly metabolised by the body, making it difficult to track the timing and duration of its effects. Additionally, these veterinary sedatives are not included in routine drug screenings or toxicology tests, meaning their presence often goes undetected by medical professionals and law enforcement, despite their potentially lethal effects.

    UK response

    While no cases of acute medetomidine toxicity have been published in the UK, the country has already experienced problems with xylazine, a similar veterinary sedative.

    British health authorities have detected xylazine in 35 cases through toxicology tests and drug seizures. Of 16 people found to have xylazine in their systems, 11 cases proved fatal – deaths that occurred primarily during May 2022 and August 2023.

    In response to the growing threat, the government has taken decisive action. Over 20 dangerous substances have been banned as part of efforts to combat synthetic drugs and improve public safety.

    Xylazine is now controlled as a class C substance, carrying penalties of up to two years in prison for possession and up to 14 years for production and supply.

    The government is also working to better equip police, healthcare workers and Border Force agents to tackle this evolving threat through improved training and detection capabilities.

    The case of medetomidine highlights a disturbing reality about modern drug policy: the illicit drug supply continues to change in unpredictable and dangerous ways. Neither medetomidine nor xylazine was developed for human consumption, and there are no human studies examining their drug interactions, lethal doses or safe reversal protocols.

    As these veterinary sedatives become more common in street drugs, the challenge for healthcare professionals continues to grow. Traditional overdose response protocols, built around reversing opioid effects with naloxone, become inadequate when faced with multi-drug combinations that affect the body through completely different mechanisms.




    Read more:
    ‘There has never been a more dangerous time to take drugs’: the rising global threat of nitazenes and synthetic opioids


    For users, families and communities already devastated by the opioid crisis, the emergence of medetomidine represents yet another layer of risk in an already dangerous landscape.

    As the drug supply becomes increasingly unpredictable, the need for comprehensive approaches to drug policy – encompassing everything from harm reduction to treatment access to law enforcement – becomes ever more urgent.

    Continue Reading

  • The Italian GP Briefing – powered by Google Cloud – McLaren

    The Italian GP Briefing – powered by Google Cloud – McLaren

    1. The Italian GP Briefing – powered by Google Cloud  McLaren
    2. Everything we’ve learned from first day at F1’s Italian GP  The Race
    3. OFFICIAL RACE PROGRAMME – 2025 Italian Grand Prix  Formula 1
    4. Carlos Sainz returns to Monza, home of the Tifosi  CarlosSainz.es
    5. F1 Italian GP: Five things to watch out for  Yahoo Sports

    Continue Reading